Treatment of chronic lymphocytic leukaemia and autoimmune complications with antibody targeted to the CD52 antigen (Campath) - the first Russian experience
Campath is a humanized monoclonal antibody targeted to the CD52 antigen. It shows efficacy with response rate of 35% in treatment of patients with chronic lymphocytic leukemia (CLL) who were refractory to fludarabine. A first-line therapy with Campath demonstrates efficacy in more than 80% of CLL pa...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/620 |
| _version_ | 1797855474103615488 |
|---|---|
| author | T. E. Byalik O. L. Timofeeva M. A. Volkova |
| author_facet | T. E. Byalik O. L. Timofeeva M. A. Volkova |
| author_sort | T. E. Byalik |
| collection | DOAJ |
| description | Campath is a humanized monoclonal antibody targeted to the CD52 antigen. It shows efficacy with response rate of 35% in treatment of patients with chronic lymphocytic leukemia (CLL) who were refractory to fludarabine. A first-line therapy with Campath demonstrates efficacy in more than 80% of CLL patients. Campath deserves a special emphasis due to effectiveness in different autoimmune cytope-nias. We describe 2 cases of CLL and autoimmune thrombocytopenia, treated with Campath. Both patients received 36 infusions of Campath. There were no severe leucopenia or anemia as well as serious infections. Stable platelet count recovery, no evidence of antiplatelet antibodies and elimination of bone marrow lymphoid infiltration were achieved after the end of the treatment. |
| first_indexed | 2024-04-09T20:24:16Z |
| format | Article |
| id | doaj.art-659f5271a52e405385580a643f05e158 |
| institution | Directory Open Access Journal |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| last_indexed | 2024-04-09T20:24:16Z |
| publishDate | 2022-11-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj.art-659f5271a52e405385580a643f05e1582023-03-30T20:15:14ZrusABV-pressОнкогематология1818-83462413-40232022-11-0101394110.17650/1818-8346-2007-0-1-39-41498Treatment of chronic lymphocytic leukaemia and autoimmune complications with antibody targeted to the CD52 antigen (Campath) - the first Russian experienceT. E. Byalik0O. L. Timofeeva1M. A. Volkova2N.N. Blokhin Russian Cancer Research Centre, Russian Academy of Medical SciencesN.N. Blokhin Russian Cancer Research Centre, Russian Academy of Medical SciencesN.N. Blokhin Russian Cancer Research Centre, Russian Academy of Medical SciencesCampath is a humanized monoclonal antibody targeted to the CD52 antigen. It shows efficacy with response rate of 35% in treatment of patients with chronic lymphocytic leukemia (CLL) who were refractory to fludarabine. A first-line therapy with Campath demonstrates efficacy in more than 80% of CLL patients. Campath deserves a special emphasis due to effectiveness in different autoimmune cytope-nias. We describe 2 cases of CLL and autoimmune thrombocytopenia, treated with Campath. Both patients received 36 infusions of Campath. There were no severe leucopenia or anemia as well as serious infections. Stable platelet count recovery, no evidence of antiplatelet antibodies and elimination of bone marrow lymphoid infiltration were achieved after the end of the treatment.https://oncohematology.abvpress.ru/ongm/article/view/620cd52campathchronic lymphocytic leukaemiaautoimmune thrombocytopenia |
| spellingShingle | T. E. Byalik O. L. Timofeeva M. A. Volkova Treatment of chronic lymphocytic leukaemia and autoimmune complications with antibody targeted to the CD52 antigen (Campath) - the first Russian experience Онкогематология cd52 campath chronic lymphocytic leukaemia autoimmune thrombocytopenia |
| title | Treatment of chronic lymphocytic leukaemia and autoimmune complications with antibody targeted to the CD52 antigen (Campath) - the first Russian experience |
| title_full | Treatment of chronic lymphocytic leukaemia and autoimmune complications with antibody targeted to the CD52 antigen (Campath) - the first Russian experience |
| title_fullStr | Treatment of chronic lymphocytic leukaemia and autoimmune complications with antibody targeted to the CD52 antigen (Campath) - the first Russian experience |
| title_full_unstemmed | Treatment of chronic lymphocytic leukaemia and autoimmune complications with antibody targeted to the CD52 antigen (Campath) - the first Russian experience |
| title_short | Treatment of chronic lymphocytic leukaemia and autoimmune complications with antibody targeted to the CD52 antigen (Campath) - the first Russian experience |
| title_sort | treatment of chronic lymphocytic leukaemia and autoimmune complications with antibody targeted to the cd52 antigen campath the first russian experience |
| topic | cd52 campath chronic lymphocytic leukaemia autoimmune thrombocytopenia |
| url | https://oncohematology.abvpress.ru/ongm/article/view/620 |
| work_keys_str_mv | AT tebyalik treatmentofchroniclymphocyticleukaemiaandautoimmunecomplicationswithantibodytargetedtothecd52antigencampaththefirstrussianexperience AT oltimofeeva treatmentofchroniclymphocyticleukaemiaandautoimmunecomplicationswithantibodytargetedtothecd52antigencampaththefirstrussianexperience AT mavolkova treatmentofchroniclymphocyticleukaemiaandautoimmunecomplicationswithantibodytargetedtothecd52antigencampaththefirstrussianexperience |